The Bloom #187 Free Edition crossdiagnostic effects

In November, I added twice as many studies to the database as in October. We have a long-term follow-up on MDMA for depression (showing promising results), possibly the most rigorous microdosing study to date (with large - but placebo-driven - effects), and a simulation of psychedelics for disorders of consciousness.

See all new studies in the full November Recap.

Floris - Founder of Blossom

ps Behind the scenes, I'm hard at work on building a completely new version of Blossom. The new version will be 'database first' and should give an even better view into psychedelic research and the road towards reimbursed care. At the start of the new year, you will likely see the new site live.

​

Latest Psychedelic Research

1 MDMA-Assisted Therapy for Major Depressive Disorder: A Seven-Month Follow-Up Proof of Principle Trial​

This long-term follow-up (n=12) of participants with moderate-to-severe major depressive disorder who received MDMA-assisted therapy (two dosing sessions integrated with nine psychotherapy sessions) found significant reductions in depression severity and functional impairment at seven months compared to baseline, with improvements maintained from the post-treatment assessment and no increases in suicidal ideation.

2 A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness​

This computational modelling study simulated the effects of LSD and psilocybin on whole-brain models of patients with disorders of consciousness, finding that both psychedelics shifted brain activity closer to criticality with greater effects in minimally conscious state patients, whilst treatment response correlated with structural connectivity in unresponsive wakefulness syndrome and baseline functional connectivity in minimally conscious state.

3 Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans​

This secondary analysis of an open-label study (n=30) of male Veterans with traumatic brain injury found that greater intensity of mystical experiences during magnesium-ibogaine treatment was associated with larger reductions in PTSD severity both immediately and one month post-treatment, as well as greater reductions in peak alpha frequency at one month.

More Research

• ​Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial​
• ​Acute experiences and persisting psychological effects associated with an encapsulated DMT-harmala alkaloid combination: results of a phase 1 study​
• ​DMT-induced shifts in criticality correlate with self-dissolution​
• ​Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial​
• ​Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity​
• ​Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial​
• ​Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults​
• ​Intact neurophysiological markers of death denial in long-term ayahuasca users​
• ​Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics​
• ​Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy​
• ​LSD microdosing in major depressive disorder: results from an open-label trial​

New on Blossom

1 Psychedelic Research Recap November​

November 2025 was a noticeably busier month for psychedelic research, with new papers landing across microdosing trials, mechanistic work on brain dynamics, and early clinical studies in highly vulnerable populations. In this recap, we start with three studies refining what microdosing can realistically offer for mood, creativity, and lived experience, before turning to a cluster of mechanistic papers on criticality and plasticity in the brain. We then look at emerging macrodose treatments for depression, PTSD, and end-of-life distress, and close with work exploring mystical experiences, 5-MeO-DMT phenomenology, and how ayahuasca use interacts with our deep-seated responses to death.

2 Psychedelic Research Links 2025​

A comprehensive overview of all psychedelic research that has come out this year. We cover the research per month and provide a one-sentence summary for each new publication. After the full summary is added, a link to Blossom's review is added to the papers included in our database.
​

Spotlight

1 M​icrodosing Facilitator Program (Course)

The Microdosing Facilitator Program by our friends at Microdosing Institute is now open for applications.

This 8-month training is designed for those who feel called to guide others with microdosing in a safe, conscious, and effective way. The program combines science, practice, and deep personal development. You’ll also learn directly from masterclass facilitators, including James Fadiman, one of the leading researchers in microdosing, with whom they proudly collaborate.

“Among the more than 50 trainings of divergent qualities which have appeared the last few years in the psychedelic wellness and healing industry, this program is a haven of integrity and professionalism.”
​— Donca Vianu, MD, Portugal – Psychiatrist, psychotherapist & former participant

Special for you: €100 discount on the program fee when you apply via me. Just make sure to select Blossom in the application form under “How did you hear about us?”

Molenvaart 76, Anna Paulowna, NH 1761AL
​Unsubscribe · Preferences​